Hepatitis C News and Research

Latest Hepatitis C News and Research

Study highlights need for greater recognition of sexual and reproductive healthcare needs of teen boys

Two newly published reports by investigators at the Johns Hopkins Children's Center highlight the need for greater recognition of the sexual and reproductive healthcare needs of teen boys and enumerate the essential services this traditionally overlooked group should receive at least once a year.

9 Dec 2011

Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV

Boehringer Ingelheim today announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California.

7 Dec 2011

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).

5 Dec 2011

Plasma can inactivate and prevent replication of adenoviruses

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

5 Dec 2011

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).

3 Dec 2011

Baby boomers more likely to develop HCV

Experts at Montefiore Medical Center urge the general public to be tested for the Hepatitis C virus, especially baby boomers, adults born between 1946-1964, who could be most at risk for this disease. Baby boomers are more likely to have been exposed to dangerous risk factors decades ago, such as sharing a drug needle, being tattooed or pierced with unsterilized tools or receiving a tainted blood transfusion.

2 Dec 2011

Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company.

2 Dec 2011

Two studies uncover limitations in screening for hepatocellular carcinoma

Two studies available in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, have uncovered limitations in screening for primary liver cancer, also known as hepatocellular carcinoma.

2 Dec 2011

EGCG may prevent HCV reinfection after liver transplantation

German researchers have determined that epigallocatechin-3-gallate (EGCG)—a flavonoid found in green tea—inhibits the hepatitis C virus (HCV) from entering liver cells.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

With HIV and unaware of it: CDC report

Over the years diagnosis with HIV/AIDS has ceased to become a death sentence. However a new Centers for Disease Prevention and Control (CDC) report says only one in four Americans with AIDS has the virus under control with adequate medication. Figures also show that about 16,000 people die from the disease annually, and the number of new infections each year in the U.S. has held steady at about 50,000 in recent years.

30 Nov 2011

Serotonin instructs scar forming cells to switch off regeneration in chronic liver disease

In liver disease, extent of tissue damage depends on the balance between the generation of scar tissue and the regeneration of new liver cells. In a significant minority of people who get injury to their organs instead of repairing them, they form scars.

29 Nov 2011

University of Liverpool introduces HEP i-chart for HCV patients

The University of Liverpool has launched an iphone app, HEP i-chart, that provides Hepatitis C (HCV) patients with quick and easy access to the latest information about drug interactions.

23 Nov 2011

Gilead enters agreement for Pharmasset acquisition

Gilead Sciences, Inc. and Pharmasset, Inc. announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.

21 Nov 2011

Research roundup: The effect of heart drug costs; Doctors' financial incentives when ordering stress tests

The researchers examined whether drug costs for heart attack patients affects health. Half of a group of more than 5,000 patients were given prescription coverage that eliminated co-payments and expanded drug choices. The others had "usual prescription coverage."

18 Nov 2011

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.

18 Nov 2011

Annual report on sexually transmitted infections reveals rising trends

New figures reveal that cases of some common sexually spread diseases continue to increase in the United States. These numbers come in the annual report on sexually transmitted disease released by health officials this Thursday.

17 Nov 2011

LGBT seniors face higher rates of disability, physical and mental distress

Aging and health issues facing lesbian, gay, bisexual and transgender baby boomers have been largely ignored by services, policies and research. These seniors face higher rates of disability, physical and mental distress and a lack of access to services, according to the first study on aging and health in these communities.

17 Nov 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Study highlights need for greater recognition of sexual and reproductive healthcare needs of teen boys

Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

Plasma can inactivate and prevent replication of adenoviruses

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

Baby boomers more likely to develop HCV

Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

Two studies uncover limitations in screening for hepatocellular carcinoma

EGCG may prevent HCV reinfection after liver transplantation

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

With HIV and unaware of it: CDC report

Serotonin instructs scar forming cells to switch off regeneration in chronic liver disease

University of Liverpool introduces HEP i-chart for HCV patients

Gilead enters agreement for Pharmasset acquisition

Research roundup: The effect of heart drug costs; Doctors' financial incentives when ordering stress tests

Inovio announces results from SynCon avian influenza vaccine Phase I study

Annual report on sexually transmitted infections reveals rising trends

LGBT seniors face higher rates of disability, physical and mental distress

Industry Focus: Cell & Gene Therapy eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Hepatitis C News and Research

Latest Hepatitis C News and Research

Industry Focus: Cell & Gene Therapy eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in